创新医疗2025年三季报显示，前三季度公司主营收入5.97亿元，同比下降2.11%；归母净利润472.44万 元，同比上升116.97%；扣非净利润-2946.98万元，同比上升6.05%；其中2025年第三季度，公司单季度 主营收入1.96亿元，同比下降3.16%；单季度归母净利润1608.57万元，同比上升236.15%；单季度扣非 净利润-1658.58万元，同比下降12.36%；负债率17.84%，投资收益2950.55万元，财务费用60.55万元， 毛利率10.08%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 1、本报告期归属于上市公司股东的净利润出现同比上升，主要系：公司增持博灵脑机股权并将该公司 纳入合并报表范围，根据《企业会计准则第 33 号——合并财务报表》第四十八条的规定，确认了相应 的投资收益；李晔案件再审改判后，建华医院收到了法院返还的被执行款项，并由此确认了营业外收 入。 2、本报告期扣除非经常性损益后的净利润出现同比下降，主要系：在医保政策以及医保支付标准持续 调整的行业背景下，康华医院、建华医院 ...

证券之星消息，创新医疗发布业绩预告，预计2025年全年扣除后营业收入:77,600万元至79,600万元。 公告中解释本次业绩变动的原因为： 2、本报告期扣除非经常性损益后的净利润出现同比下降，主要系：在医保政策以及医保支付标准持续 调整的行业背景下，康华医院、建华医院对短期盈利预期的不确定性进行了审慎评估，本报告期确认的 递延所得税资产同比减少，导致所得税费用出现同比上升。 创新医疗2025年三季报显示，前三季度公司主营收入5.97亿元，同比下降2.11%；归母净利润472.44万 元，同比上升116.97%；扣非净利润-2946.98万元，同比上升6.05%；其中2025年第三季度，公司单季度 主营收入1.96亿元，同比下降3.16%；单季度归母净利润1608.57万元，同比上升236.15%；单季度扣非 净利润-1658.58万元，同比下降12.36%；负债率17.84%，投资收益2950.55万元，财务费用60.55万元， 毛利率10.08%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 1、本报告期归属于上市公司股东的 ...

Core Insights - The Chinese Society of Science and Technology Journalism released the "Top Ten Technology Buzzwords for 2025," highlighting key areas of technological advancement and innovation in China [1] Group 1: Technology Buzzwords - AI Governance: China is leading global AI governance and has proposed the establishment of a World AI Cooperation Organization, promoting a global governance action plan [2] - Embodied Intelligence: This term was included in the government work report for the first time, signaling a push towards AI technology innovation and industry development [3] - Controlled Nuclear Fusion: The ITER organization announced the completion of all components for its reactor, marking a significant milestone in controlled nuclear fusion technology [4] - Brain-Computer Interface: Significant advancements in core technologies and applications have been made, laying a solid foundation for the industry's growth [5] - Commercial Space: China's commercial space industry is rapidly developing, with multiple private companies achieving successful rocket launches and establishing satellite manufacturing capabilities [6] - Deep-Sea Technology: This sector was included in the government work report, emphasizing its importance in emerging industries, especially in the Hainan Free Trade Port [7] - Deep Space Exploration: The successful launch of the Tianwen-2 probe marks another significant step in China's exploration of outer space [8] - Silver Economy Technology: Innovations in elder care technology are being developed to address the challenges of an aging population, with the establishment of a technology park in Shanghai [9] - Intelligent Agents: 2025 is expected to be the year of industrialization for intelligent agents, with predictions that 50% of data teams in China's top 500 companies will utilize these technologies by 2026 [10][11] - Chinese Innovation: The term "Chinese Innovation" is gaining global recognition, with China ranking in the top ten for innovation indices, showcasing remarkable achievements in technology [12]

报告期归属于上市公司股东的净利润出现同比上升，主要系：公司增持博灵脑机股权并将该公司纳入合 并报表范围，根据《企业会计准则第33号——合并财务报表》第四十八条的规定，确认了相应的投资收 益；李晔案件再审改判后，建华医院收到了法院返还的被执行款项，并由此确认了营业外收入。 格隆汇1月29日丨创新医疗(002173.SZ)公布2025年度业绩预告，预计2025年度净亏损2,600万元-3,300万 元，上年同期亏损9,395.40万元；预计2025年度扣非净亏损6,800万元-7,500万元，上年同期5,957.41万 元。 报告期扣除非经常性损益后的净利润出现同比下降，主要系：在医保政策以及医保支付标准持续调整的 行业背景下，康华医院、建华医院对短期盈利预期的不确定性进行了审慎评估，本报告期确认的递延所 得税资产同比减少，导致所得税费用出现同比上升。 ...

近期，资本市场交投氛围活跃，机构亦加快调研节奏，深入挖掘A股上市公司投资价值与潜在机会。 iFinD数据显示，2026年以来，已有670家上市公司接受了券商、公募等机构集中调研，合计调研次数达984次。其中，大金重工 （002487.SZ）、迈瑞医疗（300760.SZ）、超捷股份（301005.SZ）等企业成为机构调研的热门标的，参与调研的机构数量均超百家。 从行业与概念维度看，电子、机械设备等行业数量最多，脑机接口、商业航天等概念受追捧。 年内670家公司获机构调研 机构调研的广度与深度，直接反映出资本市场对不同行业的关注程度。根据iFinD数据，今年以来，已有670家上市公司接受了各类机构 的调研。从行业分布来看，电子、机械设备、医药生物等行业数量居前，均有60家以上，电力设备、计算机、汽车、基础化工等行业也 有超过40家企业接受调研。 近期，国家电网宣布，"十五五"时期固定资产投资预计达到4万亿元，较"十四五"时期投资增长40%。电力设备行业成为券商调研最热方 向之一，涵盖光伏、风电、电网设备、电池等板块。其中，大金重工今年以来获得209家机构调研，帝科股份（300842.SZ）接受123家 机构调研 ...

南财智讯1月29日电，创新医疗发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-3300万元—-2600万元，同比预增64.88%—72.33%；预计2025年全年归属于上市公司股东的扣除非经 常性损益的净利润为-7500万元—-6800万元，同比预减14.14%—25.89%。业绩变动原因说明：1、本报 告期归属于上市公司股东的净利润出现同比上升，主要系：公司增持博灵脑机股权并将该公司纳入合并 报表范围，根据《企业会计准则第33号——合并财务报表》第四十八条的规定，确认了相应的投资收 益；李晔案件再审改判后，建华医院收到了法院返还的被执行款项，并由此确认了营业外收入。2、本 报告期扣除非经常性损益后的净利润出现同比下降，主要系：在医保政策以及医保支付标准持续调整的 行业背景下，康华医院、建华医院对短期盈利预期的不确定性进行了审慎评估，本报告期确认的递延所 得税资产同比减少，导致所得税费用出现同比上升。 ...

Core Viewpoint - Zhejiang Qiangnao Technology Co., Ltd. has reportedly submitted a confidential IPO application to the Hong Kong Stock Exchange, with CICC and UBS as joint sponsors, indicating a significant move towards public listing in the rapidly growing brain-computer interface (BCI) sector [1][3]. Company Overview - Founded in February 2015, Qiangnao Technology focuses on the development of non-invasive brain-computer interface technology, with products spanning smart bionics, health, and education [1]. - The company has launched several products, including a smart bionic hand, a brain-machine intelligent sleep device, and an attention training system [1]. Financing History - Qiangnao Technology completed a significant financing round in early January, raising approximately 2 billion RMB, marking it as the second-largest financing in the BCI field globally, after Neuralink [3]. - Since its inception, the company has completed six rounds of financing, including a notable $400 million Series A round in 2019 [3][4]. - The latest financing rounds include a $30 million Pre-B round and a $20 million Series B round in 2025 [4]. Market Trends - The BCI sector is experiencing rapid growth, with 26 financing events in 2025 totaling 1.778 billion RMB, a significant increase from 2024 [5]. - The global BCI market is projected to grow from approximately $2.6 billion in 2024 to $2.9 billion in 2025, with a further increase to $3.3 billion by 2026 [5]. - In China, the BCI market is expected to reach 3.8 billion RMB in 2025, up from 3.2 billion RMB in 2024 [5]. Policy Support - The Chinese government is actively promoting the BCI industry, with policies aimed at fostering innovation and establishing industry clusters by 2027 and 2030 [7]. - The national strategy includes BCI as a key area for economic growth, alongside other advanced technologies [7]. Industry Outlook - Analysts predict that the BCI industry is on the verge of significant growth, driven by commercial advancements and policy support [8]. - The transition from laboratory research to commercialization is expected to accelerate, particularly with the anticipated production scale-up by Neuralink [8].

21世纪经济报道记者闫硕 脑机接口标准化建设传来新消息。 近日，国家药监局批准《采用脑机接口技术的医疗器械范式设计与应用规范运动功能重建》《采用脑机接口技术的医疗器械侵入式设备可靠性 验证方法》等2项医疗器械行业标准制修订项目立项，为采用脑机接口技术的医疗器械高质量发展提供标准支撑。 脑机接口是一种在脑与外部设备之间建立直接的通信渠道。常用于辅助、增强、修复人体的感觉–运动功能或提升人机交互能力，目前在医学 领域应用较为广泛。根据植入条件，脑机接口可分为侵入式、非侵入式和半侵入式三种。 近年来，随着神经信号处理、生物兼容材料、高性能芯片等一系列核心技术接连突破，脑机接口得以快速发展。与此同时，相关支持政策不断 落地，标准化建设成为规范行业发展、保障产品安全有效的关键抓手。 健康通副总裁、首席发展官张畅向21世纪经济报道记者表示，此次2项标准的立项是对工信部等七部门此前发布的《关于推动脑机接口产业创 新发展的实施意见》（简称《实施意见》）中标准体系建设相关内容的具体落实，同时也结合行业反馈的共性难题实现了空白填补。由此，也 为医疗领域开展相关研究、临床试验等后续"专业步骤"，迈出了有章可循的关键第一步。 强化标 ...

Group 1 - The core viewpoint highlights that the innovation drug sector is experiencing high prosperity, with a continuous net inflow of nearly 500 million yuan into the Guotai Innovation Drug ETF (589720) over the past 10 days, despite a recent pullback of over 1.3% [1] - Guotai Haitong recommends focusing on Pharma, which is expected to undergo a revaluation, and Biopharma/Biotech, which is gradually realizing its innovative pipeline and entering a performance ramp-up phase [1] - The report emphasizes investment opportunities in CXO and upstream pharmaceutical sectors benefiting from innovation and recovery, as well as in medical devices with significant engineering advantages and successful overseas expansion [1] Group 2 - Recent supportive policies from the National Healthcare Security Administration, including the release of guidelines for pricing projects related to surgical and therapeutic auxiliary operations, are expected to benefit relevant innovative surgical projects [1] - The medical device sector is seeing frequent catalysts, with investment opportunities emerging in areas such as overseas expansion, brain-computer interfaces, and AI medical applications [1] - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which has a daily price fluctuation limit of 20% and includes listed companies engaged in innovative drug research and development, covering biopharmaceuticals, chemical drugs, and traditional Chinese medicine [1]

Core Viewpoint - The article highlights the positive performance of the ChiNext Medical ETF (国泰, 159377) amid supportive policies and a focus on innovation within the pharmaceutical and medical device sectors [1]. Group 1: Industry Policies and Innovations - Recent supportive policies are continuously emerging, leading to a recommendation for innovative drugs and medical devices along with their supply chains [1]. - The high demand for innovative drugs is noted, with a recommendation for Pharma companies that are expected to see a revaluation, as well as Biopharma/Biotech firms whose performance is entering a growth phase [1]. Group 2: Investment Opportunities - The report suggests investment in CXO and upstream pharmaceutical companies that benefit from innovation and a recovery in market conditions [1]. - In the medical device sector, companies that excel in engineering and have successful overseas expansions are recommended for investment [1]. Group 3: Future Catalysts - The report mentions that from 2026 onwards, there will be frequent catalysts in the medical device sector, with a focus on investment opportunities in overseas markets, brain-computer interfaces, and AI in healthcare [1]. Group 4: ETF Performance - The ChiNext Medical ETF (国泰, 159377) tracks the Innovation Medicine Index (创医药指数, 399275), which has a daily price fluctuation limit of 20% and includes listed companies involved in the research, production, and related services of innovative drugs [1].